P073-0539 Screening compound: N-(2-{1-[(4-METHYLPHENYL)METHYL]-2-OXO-1H,2H,3H-IMIDAZO[4,5-B]PYRIDIN-3-YL}ETHYL)-1-PHENYLCYCLOPROPANE-1-CARBOXAMIDE

P073-0539 Screening compound: N-(2-{1-[(4-METHYLPHENYL)METHYL]-2-OXO-1H,2H,3H-IMIDAZO[4,5-B]PYRIDIN-3-YL}ETHYL)-1-PHENYLCYCLOPROPANE-1-CARBOXAMIDE
P073-0539 Screening compound: N-(2-{1-[(4-METHYLPHENYL)METHYL]-2-OXO-1H,2H,3H-IMIDAZO[4,5-B]PYRIDIN-3-YL}ETHYL)-1-PHENYLCYCLOPROPANE-1-CARBOXAMIDE alternative view

Chemical Structure Depiction of ChemDiv screening compound P073-0539
N-(2-{1-[(4-METHYLPHENYL)METHYL]-2-OXO-1H,2H,3H-IMIDAZO[4,5-B]PYRIDIN-3-YL}ETHYL)-1-PHENYLCYCLOPROPANE-1-CARBOXAMIDE

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

P073-0539

Molecular Formula

C26H26N4O2 (C26 H26 N4 O2)

Compound Name

N-(2-{1-[(4-METHYLPHENYL)METHYL]-2-OXO-1H,2H,3H-IMIDAZO[4,5-B]PYRIDIN-3-YL}ETHYL)-1-PHENYLCYCLOPROPANE-1-CARBOXAMIDE

IUPAC name

N-(2-{1-[(4-methylphenyl)methyl]-2-oxo-1H2H3H-imidazo[45-b]pyridin-3-yl}ethyl)-1-phenylcyclopropane-1-carboxamide

SMILES

Cc1ccc(CN(c2c(N3CCNC(C4(CC4)c4ccccc4)=O)nccc2)C3=O)cc1

InChI

InChI=1S/C26H26N4O2/c1-19-9-11-20(12-10-19)18-30-22-8-5-15-27-23(22)29(25(30)32)17-16-28-24(31)26(13-14-26)21-6-3-2-4-7-21/h2-12,15H,13-14,16-18H2,1H3,(H,28,31)

InChI Key

PVZFXCXLLBETDN-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27562447

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

426.52

Hydrogen Bond Acceptors Count

5.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

8.00

Number of Nitrogen and Oxygen Atoms

6

Partition Coefficient, logP

4.153

Distribution Coefficient, logD

4.153

Water Solubility, LogSw

-4.01

Polar Surface Area

52.936

Acid Dissociation Constant (pKa)

14.18

Base Dissociation Constant (pKb)

5.05

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

26.90

P073-0539 in Drug Discovery

Included in Screening Libraries

3D-Pharmacophore Based Diversity Library (49813 compounds)

Allosteric Kinases Inhibitors Library (23117 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

C-Met Library (15277 compounds)

Macl-GPIb alpha Interaction Library (22969 compounds)

Nonpeptide Peptidomimetics PPI Library (18997 compounds)

Protein-Protein Interaction Library (218420 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Female
  • Congenital
  • Skin
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Endocrine
  • Hemic and lymphatic
  • Cardiovascular
Targets:
  • Kinases
  • Kinases
Mechanism of action:
  • Receptor's ligands
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics

References: we are preparing a list of scientific research reports with P073-0539 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound P073-0539?
Check Price and Availability of P073-0539, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of P073-0539 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for P073-0539
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for P073-0539
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of P073-0539 available by request